CSPC Pharmaceutical Receives China Approvals for Three Clinical Trials
Mar 05, 2026
CSPC Pharmaceutical Group has received approval from China's National Medical Products Administration to begin clinical trials for three drug candidates: a hemophilia A biosimilar, a long-acting pain medication, and an injection designated SYH9089.